Carlyle, SK Capital Partners disclose expected closing date of bluebird bio deal
Carlyle, SK Capital Partners disclose expected closing date of bluebird bio deal
Bluebird bio soars on amended deal with Carlyle, SK Capital
bluebird bio confirms Ayrmid has not delivered binding offer, shares dive 9%
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more
bluebird bio sees higher offer for company from Ayrmid Pharma
bluebird bio stock slides for second day on buyout news
48.67MUSD
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US09609G2093
CUSIP
09609G100
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
0.32
Book Value
-5.91
Dividend Share
-
Dividend Yield
-
Earnings Share
-20.59
Wall Street Target Price
8.00
EPS Estimate Current Year
-11.28
EPS Estimate Next Year
-5.00
EPS Estimate Current Quarter
-4.635
EPS Estimate Next Quarter
-1.91
Most Recent Quarter
-
Revenue TTM
103,946,000
Gross Profit TTM
28,193,000
EBITDA
-149,196,000
Profit Margin
-192.39%
Return On Assets TTM
-28.37%
Return On Equity TTM
-546.54%
Revenue Per Share TTM
10.703
Qtly Revenue Growth YOY
108.40%
Diluted Eps TTM
-20.59
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
0.4682
Price Book MRQ
0.726
Enterprise Value Revenue
1
Enterprise Value EBITDA
-1
162.19
6.58%258.27
2.78%305.31
0.55%447.41
0.20%0.00
0.00%179.39
0.00%90.68
-2.58%79.74
-1.56%573.50
-0.54%485.25
-0.53%